Cohort study evaluating the efficacy of denosumab to protect against aromatase inhibitor-induced bone loss in Japanese breast cancer patients.

Cohort study evaluating the efficacy of denosumab to protect against aromatase inhibitor-induced bone loss in Japanese breast cancer patients. - Cohort study evaluating the efficacy of denosumab to protect against aromatase inhibitor-induced bone loss in Japanese breast cancer patients. (CYBORG003)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000014954

Enrollment

500

Registered

2014-08-26

Start date

2014-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer Osteoporosis

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Non-metastatic breast cancer patients within 6 months after commencing postoperative aromatase inhibitor treatment. 2. Bone mineral densities have been measured within 1 month before/after commencing aromatase inhibitor treatment. 3. Subject is willing and able to provide signed consent.

Exclusion criteria

Exclusion criteria: 1. Subject with prior allergy history to therapeutic agents used in this study 2. Evidence of with hypocalcemia 3. Known renal deficiency 4. Any organic or psychiatric disorder that, in the opinion of the investigator, might prevent the subject from completing the study or interfere with the interpretation of the study results.

Design outcomes

Primary

Measure	Time frame
Bone mineral density changes	—

Countries

Japan

Contacts

Public ContactTAKAFUMI SANGAI

Chiba University Graduate School of Medicin Department of General Surgery

sangai-jpn@umin.net043-226-2269

Outcome results